NEUROONE MEDICAL TECHNOLOGIES Corp: Annual Meeting Update

Here is the latest news from NeuroOne Medical Technologies. I have removed the complex financial jargon so you can clearly understand the results of their recent annual meeting and what they mean for your portfolio.

1. What happened?

On April 3, 2026, shareholders voted on two major business decisions:

• Reverse Stock Split: Shareholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-15. This combines multiple existing shares into one, which increases the price per share while reducing the total number of shares you hold.
• Expanded Employee Stock Plan: Shareholders approved an update to the 2025 Equity Incentive Plan. This sets aside 4.5 million shares for employee pay. It also includes an "automatic growth" feature: every January 1st from 2027 through 2031, the pool will automatically grow by 5% of the company's total shares.

2. Why did it happen?

• The Reverse Split: NeuroOne is an early-stage medical device company. By consolidating shares, the company aims to keep its stock price above the Nasdaq’s $1.00 minimum requirement. Falling below this price risks delisting, which would make it harder to trade the stock.
• The Incentive Plan: NeuroOne relies on specialized talent to develop its electrode technology. With limited cash on hand, the company is using stock instead of cash to pay employees. This preserves their remaining funds for research and product sales.

3. Why does this matter?

Think of the reverse split as a cosmetic change to the stock price. It does not change the company’s actual value or its profit.

The incentive plan is more important for the long term. By setting aside 4.5 million shares and adding a 5% annual increase, the company is signaling that it is in "growth mode." They are preparing to hire more staff to support their Evo and Cortodesign platforms. This automatic increase acts as a long-term budget for hiring, allowing them to pay staff competitively without needing shareholder approval every year.

4. Who is affected?

• Investors: Your total investment value remains the same, but you will own fewer shares at a higher price. Also, the annual 5% increase in the share pool means your ownership percentage will be spread thinner over time. This reduces your relative voting power and the potential earnings per share.
• The Company: Management now has the tools to boost the stock price and a clear plan to pay their team for the next five years. This helps them keep the experts needed to navigate complex FDA regulations.

5. What happens next?

The Board of Directors can trigger the reverse split at any time within the approved range. Keep an eye out for a follow-up filing that will specify the exact ratio and the date it takes effect.

6. What should you look for before investing?

• Don’t be fooled by the split: It is a mechanical adjustment, not a sign of sudden profit. The company is still in the early stages. Focus on their revenue growth and how fast they spend their cash.
• Watch for dilution: The new plan is generous. While it helps keep talent, issuing more shares can lower the value of your current holdings. Check the "Weighted Average Shares Outstanding" in future reports to see how many new shares the company issues.
• Monitor the cash runway: Because the company is using stock to pay for operations, their ability to reach profitability before running out of cash is the most critical factor for your investment.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before making any trading decisions.